CRISPR cell and gene therapies are predicted to be the future of medicine, yet developing these therapies presents researchers with a variety of challenges. Ensuring the quality, efficacy, and consistency of new drug products while navigating the complex regulatory space requires high-quality reagents, scalable manufacturing, and expert assistance. As a leader in CRISPR editing, Synthego can help translate your CRISPR therapy from proof-of-concept research all the way through to clinical trials with ease.

Progress through the clinical development pipeline with confidence. In this webinar, Dr. Robert Deans, Synthego’s Chief Scientific Officer, and Beckinam Nowatzke, our Senior Director of Quality and Regulatory, explain:

  • How the launch of Synthego’s new state-of-the-art sgRNA manufacturing facility allows for scalable and efficient production of high-quality, synthetic sgRNAs for confident CRISPR therapies
  • The full spectrum of Synthego’s sgRNA offerings, including large-scale RUO, GMP-like, and GMP-grade sgRNAs for clinical use
  • Synthego’s commitment to partnership, providing unparalleled CRISPR expertise and regulatory support at every step of the journey

Download the Forge a Successful CRISPR Therapeutic Path with High-Quality GMP sgRNA webinar today!